Okomera
Automated 3D organoid screening technology
France
30 employees
Grant
Total: $11.70M
Biotechnology, Health and Wellness +1
General Information
France
BounceWatch is an independent company data service, not affiliated with Okomera. To contact Okomera, visit okomera.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Okomera compare?
A PDF of Okomera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Okomera soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
France Market
Biotechnology
About Okomera
Business keywords: Biotech, Drug Discovery, 3D Organoid Screening, Precision Medicine, Cancer Research, Automation Technology, Tumor Biopsy Research, Preclinical Predictivity, CRISPR Technology, T-cell Assays, Cytotoxicity Assays
Services & Products
Target Customers
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | €1.50M | 1 |
|
21 Oct 2024 |
| Grant | Undisclosed | 1 |
|
20 Dec 2023 |
| Seed Round | €10.20M | 5 |
|
20 Dec 2023 |
| Non Equity Assistance | Undisclosed | 1 |
|
01 Jun 2020 |
Okomera Alternatives & Competitors
View All Alternatives
Capturing the Complexity of the Human Gut
An innovative and dynamic biotech start-up, unlocking the potential of stem cells and nanotechnology...
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...
FAQ About Okomera
Source: BounceWatch company record for Okomera, https://bouncewatch.com/company/okomera, updated 11 June 2025. When citing, please name BounceWatch and link this page.
